An effective IT strategy medical device manufacturers UK programme has to do something most generic IT strategies skip: align technology and data flows directly to MHRA expectations, ISO 13485 quality management, IEC 62304 software lifecycle (with Edition 2 due in 2026), IEC 81001-5-1 cybersecurity, ISO 14971 risk management, UKCA marking and the long EU MDR transition, while still running cleanroom production, electronic batch records and post-market surveillance. With the IT strategy now sitting inside the safety case, every IT and OT decision has the potential to affect patient outcomes.
Last updated: 10 May 2026
What an IT strategy medical device manufacturers UK roadmap must cover
The UK medtech sector remains one of the country’s most strategic and most regulated. According to the Association of British HealthTech Industries (ABHI) resource hub, the sector employs more than 137,000 people, contains around 4,360 medtech businesses, and contributes around £33 billion in turnover, with strong concentrations in the South East, North West and Yorkshire. The recently announced ABPI 2026 collaboration on medical device regulation between the MHRA, NICE and the US FDA reinforces that UK medtech is being positioned for accelerated patient access alongside tougher regulatory expectations.
An IT strategy medical device manufacturers UK programme therefore has to cover seven domains:
- ISO 13485-validated quality management with electronic QMS, eDHR, eDHF and DMR control.
- IEC 62304 software lifecycle, with Edition 2 (expected August 2026) reshaping process rigor and AI/ML expectations.
- IEC 81001-5-1 cybersecurity by design, integrated through the software development lifecycle.
- ISO 14971 risk management and post-market surveillance flows, fed by real-world data.
- MHRA and UKCA conformity, plus EU MDR/IVDR for products supplied into the EU.
- OT cybersecurity for cleanroom production, packaging, sterilisation and serialisation lines.
- Traceability, software bills of materials (SBOMs) and post-market vulnerability handling.
Treating any of these as a side project is the most common failure mode. The IT strategy medical device manufacturers UK plan should bring them onto a single, board-approved roadmap with one technology leader accountable for the whole.
IEC 62304 Edition 2 and the 2026 software-lifecycle reset
IEC 62304 has been the global standard for medical device software lifecycle processes for almost two decades. Edition 2, expected to publish around August 2026, is a structural overhaul rather than a minor update. Independent industry analysis summarises the headline changes:
- The three safety classes (A, B, C) are replaced by two Software Process Rigor Levels (I and II), driven by software risk to patients.
- Scope expands from medical device software (MDSW) to all health software, recognising the breadth of digital health products.
- A new clause and annex address AI/ML lifecycle, including data governance, model validation and post-deployment monitoring.
- Cybersecurity becomes a design control, with explicit integration of threat modelling, security architecture and security verification, referencing IEC 81001-5-1.
- ISO 13485 and ISO 14971 are removed as normative references, but remain practically inseparable in audit practice.
For UK manufacturers, the IT strategy medical device manufacturers UK plan must include an Edition 2 readiness workstream: gap assessment, toolchain refresh (ALM, requirements, test management, SBOM tooling, threat modelling), and a prioritised remediation plan for the riskiest software products first. Manufacturers can adopt Edition 2 voluntarily as soon as it publishes; assessors will increasingly expect it.
MHRA, UKCA and the long EU MDR transition
UK medtech sits in a multi-track regulatory environment. In Great Britain (England, Scotland and Wales), CE-marked devices may continue to be placed on the market until 30 June 2028 or 30 June 2030 depending on the EU legislation they comply with. The MHRA’s guidance on regulating medical devices sets out a phased move to UKCA, with new UK MDR statutory instruments progressing alongside post-market surveillance and IVD changes. The MHRA has launched a consultation on indefinite recognition of CE marking, with higher-risk devices subject to additional UK Approved Body review.
The IT strategy implications are direct. UK medtech manufacturers usually need:
- Parallel technical documentation flows for UKCA, CE marking under EU MDR, and (where relevant) FDA submissions.
- Distinct registration data sets for the MHRA Devices Online Information System and the EUDAMED database.
- Evidence pipelines for both EU MDR’s PMS, PMCF and PMSR processes and the UK’s evolving post-market surveillance obligations.
- Northern Ireland-specific data flows under the Windsor Framework, where CE/EU MDR continues to apply.
- Clear ownership of regulatory IT systems, eQMS, eIFU, label and SDS authoring and lifecycle change.
This is not optional administration. Failing to maintain UKCA-ready and EU MDR-ready documentation has direct consequences for market access and revenue.
Cybersecurity, SBOMs and post-market vulnerability handling
Medical device cybersecurity has become one of the most consequential parts of any IT strategy medical device manufacturers UK plan. The 2026 RunSafe Security Medical Device Cybersecurity Index, surveying 551 healthcare professionals across the US, UK and Germany, shows that 24% of organisations have suffered a cyberattack via a vulnerability in a medical device, up from 22% in 2025, and 80% of those affected report a moderate or significant impact on patient care. Procurement is hardening: 56% of healthcare buyers have rejected a medical device on security grounds, up from 46% the prior year, and 81% rate SBOMs as important or essential.
For UK medtech manufacturers, this drives several IT strategy priorities:
- Security by design. IEC 81001-5-1 architecture, threat modelling, secure coding standards and security verification embedded in the SDLC.
- Software bills of materials (SBOMs). Generated automatically during build, distributed to customers, maintained for the lifetime of the device.
- Vulnerability management. Continuous scanning of components, coordinated disclosure, secure update channels and clear customer communications.
- Authentication and authorisation. Strong default credentials, role-based access, and where appropriate phishing-resistant MFA for clinical users.
- Incident response. Post-market vulnerability disclosure aligned to NCSC, FDA and EU expectations, integrated with quality and complaint handling.
- AI/ML governance. Specific evaluation criteria for AI-enabled and AI-assisted devices, including model manipulation, data poisoning and adversarial input risks.
Failure to evidence these is now a market-access issue, not just a compliance one. Healthcare procurement teams increasingly disqualify devices that cannot show the controls.
Quality, traceability and the validated IT estate
UK medtech production tends to combine cleanroom assembly, sterilisation, packaging, serialisation and electronic and electromechanical sub-systems. The IT estate has to support each step under ISO 13485 with auditable records:
- eQMS. Validated electronic QMS handling document control, training records, CAPA, complaints, supplier management and audits.
- Design controls. Design History File, Device Master Record and Design Inputs/Outputs traced through requirements, risk and verification.
- Production records. Electronic Device History Records (eDHRs), in-process inspection, sterilisation cycle data and final acceptance.
- Traceability. Component, sub-assembly, serial number and UDI traceability for recall in hours.
- LIMS and clinical data integration. Where IVD or companion-diagnostic data flows are required.
- Post-market surveillance. Complaints, adverse event reporting (MORE in the UK, EUDAMED in EU), PSUR/PMCF cycles.
- Validated cloud and SaaS. Cloud platforms qualified under shared-responsibility models with right-to-audit and continuous validation.
Sector-specific systems and integrators almost always beat generic distribution-led ERPs for UK medtech. The IT strategy should pick platforms that can be validated, not retrofit-validated.
OT cyber, serialisation and the connected production line
Medtech production environments are increasingly connected: cleanroom monitoring, sterilisation cycle data, vision inspection, automated assembly, packaging serialisation and warehouse automation. Aligning to the NCSC Operational Technology collection and the January 2026 Secure Connectivity Principles for OT is now baseline practice. UK medtech manufacturers should:
- Segregate OT networks from corporate IT and validate the boundary controls.
- Apply phishing-resistant MFA to vendor remote access for production and inspection systems.
- Treat serialisation systems as GxP-relevant with appropriate validation and audit trails.
- Integrate OT events into the wider quality data integrity framework rather than a separate silo.
- Maintain documented incident-response runbooks for ransomware on a packaging line.
- Ensure Cyber Essentials Plus as a minimum, ISO 27001 where customers demand, and ISO 27799-aligned controls for any patient data flows.
How to choose a partner for a UK medtech IT strategy
Generic fractional CIOs rarely understand ISO 13485, IEC 62304 or MHRA inspections. When choosing a partner for an IT strategy medical device manufacturers UK programme, look for:
- Real medtech experience, including ISO 13485 audits, MHRA inspections and EU MDR/IVDR transitions.
- Working knowledge of IEC 62304 (and Edition 2 readiness), IEC 81001-5-1, ISO 14971 and EN 62366 usability.
- Validation experience across eQMS, ALM, requirements management and SBOM tooling.
- Vendor independence: no commission on eQMS, ERP, MES or AI/ML platforms.
- Fixed-fee retainers, no long-term tie-in, board-ready communication.
- Track record with UK, EU and US regulatory submissions, plus Notified Body and Approved Body interaction.
If the candidate cannot describe the difference between Edition 1 and Edition 2 of IEC 62304, or how an SBOM is generated and maintained for a connected device, they are not yet ready for a UK medtech engagement.
Frequently Asked Questions
What does an IT strategy for a UK medical device manufacturer have to cover?
It must cover ISO 13485-validated quality management systems, IEC 62304 software lifecycle and the upcoming Edition 2 changes, IEC 81001-5-1 cybersecurity, ISO 14971 risk management, MHRA and UKCA conformity, EU MDR/IVDR transition, eQMS, electronic device history records, design history files, post-market surveillance, traceability, OT cybersecurity for production lines, and software bills of materials (SBOMs). It is broader and more risk-sensitive than a generic manufacturing IT strategy because every system can affect product safety and patient outcomes.
How does IEC 62304 Edition 2 change UK medtech IT planning in 2026?
IEC 62304 Edition 2, expected to publish around August 2026, replaces the three safety classes (A, B, C) with two Software Process Rigor Levels (I and II), expands scope from medical device software to all health software, adds explicit AI/ML lifecycle requirements, and integrates cybersecurity directly as a design control via IEC 81001-5-1. UK medtech manufacturers should treat the IT strategy as the place to plan their toolchain, evidence and validation upgrades for Edition 2, alongside MHRA and UKCA submissions.
What MHRA and UKCA timelines do UK medical device manufacturers need to plan for?
In Great Britain, CE-marked medical devices may be placed on the market until 30 June 2028 or 30 June 2030 depending on device class and the EU regulation they comply with, after which UKCA is expected to be required. The MHRA is currently consulting on indefinite recognition of CE marking, with separate streams for higher-risk devices. New UK MDR statutory instruments are progressing through Parliament alongside post-market surveillance and IVD changes. The IT strategy should support both UKCA and CE technical documentation flows.
What cybersecurity requirements apply to UK medical devices in 2026?
UK medical device manufacturers should align with IEC 81001-5-1 for security architecture, the FDA premarket cybersecurity guidance for any US-bound products, EU MDR cybersecurity expectations for CE-marked devices, and the upcoming integrated cybersecurity controls in IEC 62304 Edition 2. Practical requirements include software bills of materials (SBOMs), threat modelling, vulnerability management, secure update mechanisms, incident response and post-market vulnerability disclosure. NCSC OT guidance and Cyber Essentials Plus apply at the manufacturing site.
Take the Next Step
If you are a UK medical device manufacturer preparing for IEC 62304 Edition 2, an MHRA inspection, UKCA conformity or a major eQMS programme, Bailey & Associates can build the IT strategy medical device manufacturers UK roadmap with you. We work exclusively with UK manufacturers, on a fixed monthly retainer from £2,000 per month with no tie-in and cancel-anytime terms. Fifteen-plus years of UK manufacturing IT experience including regulated medtech production, vendor-neutral, board-ready. Learn more about our manufacturing IT services or book a free discovery call today.
